Inhibition of nonsense-mediated decay turns immunologically cold tumors hot by increasing the amount of mutant RNA leading to an increase in T-cell-targetable neoantigens on the cell surface.

Turning groundbreaking research from the Institut Pasteur with the support of Argobio’s start-up studio, into novel treatments for cancer, inflammatory diseases and viral infections. The platform ...

Kymera has $900 million in cash and no long-term debt, funding operations into mid-2027. Click here to read an analysis of ...

Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

This content introduces the physiological and pathological importance of protein kinases, kinase inhibitors approved for ...

If successful, Mankind’s drug would be the first oral small-molecule alternative, offering a pill-based treatment.

Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 –– Biomarker ...

Relay Therapeutics, Inc.’s RLAY share price has dipped by 13.33%, which has investors questioning if this is right time to ...

It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein ...

TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25New ...